Reports of preliminary merger talks between AstraZeneca and Bristol Myers Squibb have been denied by a senior source close to the matter. AstraZeneca's stock experienced a significant drop of approximately 9% in response to the initial speculation. In separate corporate news, JPMorgan Chase is strengthening its shareholder engagement capabilities by hiring Amy Lissauer from Bank of America. Lissauer will assume the role of global head of Shareholder Engagement and M&A Capital Markets in New York.
Speculation regarding preliminary merger talks between pharmaceutical giants AstraZeneca and Bristol Myers Squibb has been officially denied. A senior source with direct knowledge of the situation stated that no ongoing discussions concerning a potential deal are occurring between the two companies. This denial follows earlier reports that had suggested preliminary merger discussions were underway. The initial speculation had a notable impact on AstraZeneca's stock, which slid approximately 9% in the market following the unconfirmed reports. The company's share price decline underscores the market's sensitivity to potential major corporate transactions.
In parallel, JPMorgan Chase is making a strategic move to enhance its shareholder engagement and advisory services. The financial institution has announced the hiring of Amy Lissauer, a notable executive from Bank of America. Lissauer is set to join JPMorgan Chase later this year, taking on the significant role of global head of Shareholder Engagement and M&A Capital Markets. Her new position will be based in New York, where she will lead efforts in advising clients on shareholder relations and mergers and acquisitions capital strategies. This hire signals JPMorgan Chase's commitment to expanding its expertise in navigating complex corporate finance landscapes and activist investor relations.
Speculation regarding preliminary merger talks between pharmaceutical giants AstraZeneca and Bristol Myers Squibb has been officially denied. A senior source with direct knowledge of the situation stated that no ongoing discussions concerning a potential deal are occurring between the two companies. This denial follows earlier reports that had suggested preliminary merger discussions were underway. The initial speculation had a notable impact on AstraZeneca's stock, which slid approximately 9% in the market following the unconfirmed reports. The company's share price decline underscores the market's sensitivity to potential major corporate transactions.